Skin Reaction to Adalimumab

Arthritis and Rheumatism

Volumn 50, Issue 5, 2004, Pages 1690-1692

  Beuthien, W ^a   Mellinghoff, H U ^a   Von Kempis, J ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; ERYTHEMA MULTIFORME; FEMALE; HUMAN; IMMUNOMODULATION; PATHOGENESIS; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SKIN EXFOLIATION; SKIN MANIFESTATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; ERYTHEMA MULTIFORME; FEMALE; FOOT; HAND; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342500840     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20155     Document Type: Article

References (15)

1. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correira O, Schroeder W, Roujeau JC, for the Severe Cutaneous Adverse Reactions Study Group. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-24.
2. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;45:35-45.
3. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor α receptor:Fc fusion protein. Arch Dermatol 2001;137:893-9.
4. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4.
5. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999;131:634.
6. Remicade (infliximab) prescribing information. Malvern (PA): Centocor; 2003.
7. Devos SA, van den Bosche N, de Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-α monoclonal antibody therapy. Dermatology 2003;206:388-90.
8. Kent PD, Davis JM III, Davis MD, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis [letter]. Arthritis Rheum 2002;46:2257-8.
9. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruptions to infliximab: report of 4 cases with an interface dermatitis pattern [letter]. Arch Dermatol 2002;138: 1258-9.
10. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
11. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
12. DeBrandt MJ, Descamps V, Meyer O. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2001;60:175.
13. Shakoor N, Michalska M, Harris CA, Block JA. Drug induced lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
14. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997;19: 127-32.
15. Berg L, Lampa J, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors. Ann Rheum Dis 2001;60:133-9.